Wyeth Analyzing MYO-029 Results

Wyeth Pharmaceuticals has told MDA that results of its trial of MYO-029 in adult muscular dystrophy are being analyzed.

MYO-029, a recombinant human antibody (laboratory-developed immune-system protein), is designed to stick to and interfere with the activity of myostatin, a natural protein that prevents skeletal muscle formation. Studies conducted in mice with muscular dystrophy contributed to the development of this trial, which included approximately 100 adults with Becker, limb-girdle or facioscapulohumeral MD.

Information as it becomes available will be posted on this Web site and at www.clinicaltrials.gov (enter MYO-029 in the search box).